OpGen (NASDAQ:OPGN) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGNGet Rating) in a report released on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Trading Up 2.7 %

Shares of OpGen stock opened at $0.20 on Friday. The company’s 50-day moving average price is $0.25 and its 200-day moving average price is $0.42. The company has a market cap of $10.65 million, a price-to-earnings ratio of -0.21 and a beta of -0.27. The company has a current ratio of 1.11, a quick ratio of 1.05 and a debt-to-equity ratio of 0.29. OpGen has a 12-month low of $0.16 and a 12-month high of $1.70.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OPGN. Citadel Advisors LLC boosted its holdings in OpGen by 571.0% in the third quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85,754 shares in the last quarter. Arete Wealth Advisors LLC raised its position in shares of OpGen by 70.0% in the 1st quarter. Arete Wealth Advisors LLC now owns 85,000 shares of the medical research company’s stock worth $64,000 after purchasing an additional 35,000 shares during the last quarter. GSA Capital Partners LLP purchased a new position in OpGen in the 1st quarter worth about $73,000. Vanguard Group Inc. grew its stake in shares of OpGen by 39.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock valued at $537,000 after purchasing an additional 534,960 shares during the period. Finally, Armistice Capital LLC bought a new position in shares of OpGen during the 3rd quarter valued at approximately $1,517,000. Institutional investors own 7.24% of the company’s stock.

About OpGen

(Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.